Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in type 2 diabetes with CKD stage 3A
2015-000804-24Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Dapagliflozin 10 mg with Placebo (2 arms). Primary endpoint: Change from baseline in HbA1c at Week 24. Started May 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2015-000804-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000804-24.